Is concurrent immuno-radiation therapy a viable treatment option for patients with unresectable, non-metastatic, locally advanced lung cancer, who have high PD-L1 expression and no oncogenic mutations?

Concurrent radiation and immunotherapy would not be recommended for patients with unresectable locally advanced NSCLC.

The standard of care in this scenario is concurrent chemotherapy and radiation followed by consolidation durvalumab based on survival improvements seen with the addition of durvaluma...